Florian H Heidel

List of Publications by Year
in descending order

74 papers	2,645 citations	257101 24 h-index	197535 49 g-index
74 all docs	74 docs citations	74 times ranked	4624 citing authors

#	Article	IF	Citations
1	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia, 2019, 33, 379-389.	3.3	396
2	Genetic and Pharmacologic Inhibition of Î²-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML. Cell Stem Cell, 2012, 10, 412-424.	5.2	209
3	Oncogenic JAK2 ^{V617F} causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Science Translational Medicine, 2018, 10, .	5.8	166
4	Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-Î± in a murine model of polycythemia vera. Blood, 2013, 121, 3692-3702.	0.6	140
5	Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood, 2014, 124, 13-23.	0.6	139
6	Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Cells, 2019, 8, 854.	1.8	119
7	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer, 2020, 126, 1243-1252.	2.0	106
8	Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood, 2016, 127, 2890-2902.	0.6	96
9	JAK2-V617F promotes venous thrombosis through Î²1/Î²2 integrin activation. Journal of Clinical Investigation, 2018, 128, 4359-4371.	3.9	88
10	Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nature Communications, 2019, 10, 2031.	5.8	87
11	Telomerase Inhibition Effectively Targets Mouse and Human AML Stem Cells and Delays Relapse following Chemotherapy. Cell Stem Cell, 2014, 15, 775-790.	5.2	74
12	NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells. Leukemia, 2016, 30, 473-483.	3.3	54
13	Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments. Cells, 2020, 9, 2493.	1.8	49
14	The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML. Journal of Experimental Medicine, 2013, 210, 15-22.	4.2	47
15	Self-renewal related signaling in myeloid leukemia stem cells. International Journal of Hematology, 2011, 94, 109-117.	0.7	41
16	Plasma VCAM1 levels correlate with disease severity in Parkinsonâ€™s disease. Journal of Neuroinflammation, 2019, 16, 94.	3.1	37
17	Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. Gastric Cancer, 2007, 10, 145-152.	2.7	35
18	Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells. Nature Communications, 2017, 8, 311.	5.8	35

#	Article	IF	Citations
19	Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo. Leukemia, 2016, 30, 1220-1225.	3.3	33
20	Epo-induced erythroid maturation is dependent on PlcÎ³1 signaling. Cell Death and Differentiation, 2015, 22, 974-985.	5.0	30
21	Efficacy and safety of ruxolitinib in intermediateâ€1 IPSS risk myelofibrosis patients: Results from an independent study. Hematological Oncology, 2018, 36, 285-290.	0.8	29
22	Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. Leukemia, 2020, 34, 1075-1089.	3.3	29
23	Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. Journal of Hematology and Oncology, 2020, 13, 92.	6.9	28
24	The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML. Leukemia, 2019, 33, 2628-2639.	3.3	27
25	Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo. Leukemia, 2020, 35, 2017-2029.	3.3	27
26	SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders. Leukemia, 2020, 34, 2206-2216.	3.3	27
27	Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders. Leukemia, 2020, 34, 2198-2205.	3.3	26
28	Evolutionarily Conserved Signaling Pathways: Acting in the Shadows of Acute Myelogenous Leukemia's Genetic Diversity. Clinical Cancer Research, 2015, 21, 240-248.	3.2	25
29	Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function. Leukemia, 2016, 30, 991-995.	3.3	21
30	The Role of MacroH2A Histone Variants in Cancer. Cancers, 2021, 13, 3003.	1.7	21
31	JAK2-V617F activates Î²1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1. Leukemia, 2017, 31, 1223-1226.	3.3	20
32	Dysregulation of chemokine receptor expression and function in leukocytes from ALS patients. Journal of Neuroinflammation, 2018, 15, 99.	3.1	20
33	Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling. Cell Communication and Signaling, 2019, 17, 5.	2.7	20
34	Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry. Cancers, 2021, 13, 4086.	1.7	17
35	Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis. Leukemia, 2017, 31, 889-895.	3.3	16
36	PLCÎ³1 suppression promotes the adaptation of KRAS-mutant lung adenocarcinomas to hypoxia. Nature Cell Biology, 2020, 22, 1382-1395.	4.6	16

#	Article	IF	Citations
37	RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts. Cell Death and Differentiation, 2017, 24, 371-383.	5.0	15
38	The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function. Leukemia, 2018, 32, 1211-1221.	3.3	15
39	Epigenetic Erosion in Adult Stem Cells: Drivers and Passengers of Aging. Cells, 2018, 7, 237.	1.8	15
40	Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia. Nature Communications, 2020, 11, 3021.	5.8	15
41	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Realâ€world data. Hematological Oncology, 2020, 38, 372-380.	0.8	15
42	Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. Haematologica, 2014, 99, e90-e93.	1.7	14
43	Prediction of central venous catheterâ€"related bloodstream infections (CRBSIs) in patients with haematologic malignancies using a modified Infection Probability Score (mIPS). Annals of Hematology, 2015, 94, 1451-1456.	0.8	14
44	Leukemogenic potency of the novel FLT3-N676K mutant. Annals of Hematology, 2016, 95, 783-791.	0.8	14
45	Fibrosis and Immune Cell Infiltration Are Separate Events Regulated by Cell-Specific Receptor Notch3 Expression. Journal of the American Society of Nephrology: JASN, 2020, 31, 2589-2608.	3.0	14
46	Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2041-2049.	1.2	13
47	Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study. Leukemia, 2020, 34, 1949-1953.	3.3	13
48	Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo. Haematologica, 2016, 101, e81-e85.	1.7	11
49	Gain of function in Jak2V617F-positive T-cells. Leukemia, 2017, 31, 1000-1003.	3.3	11
50	Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia. Haematologica, 2018, 103, e505-e509.	1.7	11
51	Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature. Journal of Hematology and Oncology, 2013, 6, 39.	6.9	10
52	Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. Leukemia, 2018, 32, 2085-2087.	3.3	8
53	Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation. Oncogene, 2019, 38, 4773-4787.	2.6	8
54	Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1481-1491.	1.2	8

#	Article	IF	Citations
55	Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN. Journal of Cancer Research and Clinical Oncology, 2017, 143, 807-820.	1.2	8
56	Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair. Oncotarget, 2017, 8, 95038-95053.	0.8	8
57	SHP1 regulates a STAT6â€“ITGB3 axis in FLT3ITD-positive AML cells. Leukemia, 2020, 34, 1444-1449.	3.3	7
58	Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies. Cancers, 2021, 13, 612.	1.7	6
59	3,4-Diarylmaleimidesâ€”a novel class of kinase inhibitorsâ€”effectively induce apoptosis in FLT3-ITD-dependent cells. Annals of Hematology, 2012, 91, 331-344.	0.8	5
60	Central Venous Catheterâ€“Related Bloodstream Infections in Obese Hematologic Patients. Infection Control and Hospital Epidemiology, 2015, 36, 995-996.	1.0	5
61	Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018. Leukemia, 2018, 32, 1055-1056.	3.3	5
62	Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance. Cells, 2021, 10, 2992.	1.8	5
63	Chronic myelogenous leukemia evolving after treatment of multiple myeloma. Blood, 2016, 128, 146-146.	0.6	4
64	Kinomics Screening Identifies Aberrant Phosphorylation of CDC25C in FLT3-ITD-positive AML. Anticancer Research, 2016, 36, 6249-6258.	0.5	4
65	Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells. Antioxidants, 2022, 11, 513.	2.2	4
66	A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs. Molecular and Cellular Oncology, 2021, 8, 1871172.	0.3	3
67	Hacking the stem cell niche. Blood, 2017, 129, 2951-2952.	0.6	2
68	Diverging impact of cell fate determinants Scrib and Llgl1 on adhesion and migration of hematopoietic stem cells. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1933-1944.	1.2	2
69	Germ and Hematology: Underlying Disease Influences Diversity of Germ Spectra and Antibiotic Therapy. Infection Control and Hospital Epidemiology, 2014, 35, 208-210.	1.0	1
70	Significance of BK Polyomavirus in Long-Term Survivors after Adult Allogeneic Stem Cell Transplantation. Biology, 2021, 10, 553.	1.3	1
71	Influence of Scribble polarity complex on hematopoiesis and leukemia - a matter of where, when and how. Oncotarget, 2018, 9, 34642-34643.	0.8	1
72	A rare cause of lower back pain. Blood, 2014, 124, 165-165.	0.6	0

#	Article	IF	Citations
73	Leukemic mastopathy. International Journal of Hematology, 2016, 103, 357-358.	0.7	0
74	Macrophageâ€™s little helper: vitamin A directs alternatively activated monocyte-derived macrophages to tissue-resident macrophages. Cellular and Molecular Immunology, 2017, 14, 805-808.	4.8	0